# Antiproteinuric Effect of Valsartan and Lisinopril

> **NCT00171574** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 124 (actual)

## Conditions studied

- Hypertension
- Diabetic Nephropathy

## Interventions

- **DRUG:** Valsartan
- **DRUG:** Valsartan plus HCTZ
- **DRUG:** Lisinopril

## Key facts

- **NCT ID:** NCT00171574
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171574, "Antiproteinuric Effect of Valsartan and Lisinopril". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00171574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*